Views

CrossRef citations to date

Altmetric

Original Article: Research

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival

Vicent GuillemDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario INCLIVA Biomedical Research Institute, Valencia, Spain;

Marisa CalabuigDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario INCLIVA Biomedical Research Institute, Valencia, Spain;

Salut BrunetDepartment of Hematology, Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona, Spain;

Jordi EsteveDepartment of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain;

Lourdes EscodaDepartment of Hematology, Hospital Universitari Joan XIII, Tarragona, Spain;

David GallardoDepartment of Hematology, ICO Girona, Hospital Josep Trueta, IDIBGI Foundation, Girona, Spain;

Josep-Maria RiberaDepartment of Hematology, ICO Badalona – Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain;

http://orcid.org/0000-0003-1042-6024

María Paz Queipo de LlanoDepartment of Hematology, Hospital Virgen de la Victoria, Málaga, Spain;

Montserrat ArnanDepartment of Hematology, ICO – Hospital Duran i Reynals, Barcelona, Spain;

Carme PedroDepartment of Hematology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;

María Luz AmigoDepartment of Hematology, Hospital Morales Meseguer, Murcia, Spain;

Josep M. Martí-TutusausHospital Universitari Mútua Terrassa, Terrasa, Spain;

Antoni García-GuiñónDepartment of Hematology, Hospital Universitari Arnau de Villanova, Lleida, Spain;

Joan BargayDepartment of Hematology, Hospital Son Llatzer, Mallorca, Spain;

Antonia SampolDepartment of Hematology, University Hospital Son Espases, Instituto IDISPA, Palma de Mallorca, Spain;

Olga SalameroDepartment of Hematology, Hospital Vall d’Hebron, Barcelona, Spain;

Llorenç FontDepartment of Hematology, Hospital Verge de la Cinta, Tortosa, Spain

Carme TalarnDepartment of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain;

Montserrat HoyosDepartment of Hematology, Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona, Spain;

Marina Díaz-BeyáDepartment of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain;

Ana GarridoDepartment of Hematology, Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona, Spain;

Blanca NavarroDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario INCLIVA Biomedical Research Institute, Valencia, Spain;

Josep NomdédeuDepartment of Hematology, Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona, Spain;

Jordi SierraDepartment of Hematology, Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona, Spain;

Mar TormoDepartment of Hematology and Medical Oncology, Hospital Clínico Universitario INCLIVA Biomedical Research Institute, Valencia, Spain; Correspondence[email protected]

http://orcid.org/0000-0001-9622-1649

show all

Supplemental material

Supplementary Material#3: Relationship between VEGFC expression in AML patients and continuous variables (Pearson test).

Download MS Word (15.8 KB)

Supplementary Material #2: Gene Expression Protocols

Download MS Word (18.6 KB)

Supplementary Material #1: Treatment schedules from AML-03 protocol

Download MS Word (17.3 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival

ICMJE Form for Disclosure of Potential Conflicts of Interest

Supplementary Material #6

Supplementary Material #5

Supplementary Material #4

Supplementary Material#3: Relationship between VEGFC expression in AML patients and continuous variables (Pearson test).

Supplementary Material #2: Gene Expression Protocols

Supplementary Material #1: Treatment schedules from AML-03 protocol

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival

ICMJE Form for Disclosure of Potential Conflicts of Interest

Supplementary Material #6

Supplementary Material #5

Supplementary Material #4

Supplementary Material#3: Relationship between VEGFC expression in AML patients and continuous variables (Pearson test).

Supplementary Material #2: Gene Expression Protocols

Supplementary Material #1: Treatment schedules from AML-03 protocol

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date